Skip to search formSkip to main contentSkip to account menu

CB-839

Known as: Glutaminase Inhibitor CB-839 
An orally bioavailable inhibitor of glutaminase, with potential antineoplastic activity. Upon oral administration, CB-839 selectively and… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

BenzeneacetamidesThiadiazoles
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Targeting MTOR and metabolic pathways for anti-tumour therapy in a TSC2+/- mouse model
Tuberous sclerosis (TSC) is a genetic tumour syndrome characterised by the formation of tumours in multiple organs, including the… 
2017
2017
Abstract P6-11-05: Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), in combination with paclitaxel (Pac) in patients (its) with triple negative breast cancer (TNBC)
Background: CB-839 is a first-in-class highly selective inhibitor of GLS, a key enzyme in the utilization of glutamine by cancer… 
2017
2017
Abstract 430: Combination of CB-839 and everolimus is effective in inhibiting growth of endocrine resistant breast cancer in vivo
2016
2016
Everolimus, CB-839 Combination Active in Advanced RCC
The combination of CB-839, a selective inhibitor of glutaminase, and everolimus seems to have disease activity in patients with… 
2014
2014
Small Molecule Therapeutics Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
Glutamine serves as an important source of energy andbuilding blocks formany tumor cells. Thefirst step in glutamine utilization…